ArticleAnnals of surgical oncology2025
miRNAs Associated with Axillary Lymph Node Metastasis in Breast Cancer: A Systematic Review and Meta-Analysis.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSome microRNAs (miRNAs) may have potential as biomarkers for axillary lymph node metastasis (ALNM) in breast cancer.
methodsPubMed was systematically searched from its inception to October 2023 using the search term 'miRNA and breast cancer lymph node metastasis' to identify miRNAs reported in three or more relevant publications. Each qualifying miRNA was then paired with 'breast cancer' as search terms across four databases (PubMed, Embase, Web of Science, and Cochrane Library) covering the same time span. Studies investigating miRNA associations with ALNM in breast cancer were included and the evaluation indicators (odds ratio [OR]) or standardized mean difference [SMD]) were calculated.
resultsNine miRNAs were frequently reported to be associated with breast cancer ALNM: miR-206, miR-21, miR-155, miR-124, miR-10b, miR-30a, miR-200c, miR-4521, and miR-101. Patients with high expression of miR-155 (OR 3.41 [1.92-6.06]) or low expression of miR-200c (OR 0.36 [0.17-0.77]) were more likely to experience ALNM. Compared with patients without lymph node metastasis, patients with positive ALNM had elevated expression levels of miR-21 (SMD 1.39 [0.66-2.13]), miR-155 (SMD 0.91 [0.17-1.65]), and miR-10b (SMD 0.63 [0.02-1.23]), and decreased expression levels of miR-200c (SMD - 0.44 [- 0.84 to - 0.05]) and miR-124 (SMD - 2.29 [- 3.93 to - 0.65]).
conclusionHigh expression of miRNA-155, miRNA-21, and miRNA-10b, and low expression of miRNA-200c and miRNA-124, were significantly correlated with ALNM in breast cancer patients. miRNAs are expected to become biomarkers for predicting ALNM in breast cancer patients, although more clinical trials are needed for validation.
Indexed as
Identifiers
40783663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.